Johnson & Johnson $JNJ Shares Sold by Jackson Thornton Wealth Management LLC

Jackson Thornton Wealth Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 32.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,666 shares of the company’s stock after selling 1,287 shares during the quarter. Jackson Thornton Wealth Management LLC’s holdings in Johnson & Johnson were worth $415,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Brighton Jones LLC boosted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new position in Johnson & Johnson in the 1st quarter valued at about $218,000. GAMMA Investing LLC boosted its holdings in Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after purchasing an additional 14,118 shares during the last quarter. Center for Financial Planning Inc. boosted its holdings in Johnson & Johnson by 0.7% in the 1st quarter. Center for Financial Planning Inc. now owns 14,710 shares of the company’s stock valued at $2,440,000 after purchasing an additional 107 shares during the last quarter. Finally, LVZ Inc. acquired a new position in Johnson & Johnson in the 1st quarter valued at about $214,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on JNJ shares. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday. Morgan Stanley set a $190.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 15th. Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. HSBC boosted their target price on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Finally, Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $200.06.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $191.93 on Wednesday. The firm’s 50 day moving average price is $181.27 and its 200-day moving average price is $165.37. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The firm has a market cap of $462.23 billion, a P/E ratio of 18.53, a P/E/G ratio of 2.28 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion for the quarter. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.